BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 11041022)

  • 1. Optimal timing of administration of hyperthermia in combined radioimmunotherapy.
    Kinuya S; Yokoyama K; Hiramatsu T; Konishi S; Watanabe N; Shuke N; Aburano T; Bunko H; Michigishi T; Tonami N
    Cancer Biother Radiopharm; 2000 Aug; 15(4):373-9. PubMed ID: 11041022
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced efficacy of radioimmunotherapy combined with systemic chemotherapy and local hyperthermia in xenograft model.
    Kinuya S; Yokoyama K; Konishi S; Hiramatsu T; Watanabe N; Shuke N; Aburano T; Takayama T; Michigishi T; Tonami N
    Jpn J Cancer Res; 2000 May; 91(5):573-8. PubMed ID: 10835504
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature.
    Tijink BM; Neri D; Leemans CR; Budde M; Dinkelborg LM; Stigter-van Walsum M; Zardi L; van Dongen GA
    J Nucl Med; 2006 Jul; 47(7):1127-35. PubMed ID: 16818947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Feasibility of 186Re-radioimmunotherapy for treatment in an adjuvant setting of colon cancer.
    Kinuya S; Yokoyama K; Izumo M; Sorita T; Obata T; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
    J Cancer Res Clin Oncol; 2003 Jul; 129(7):392-6. PubMed ID: 14605881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination radioimmunotherapy with local hyperthermia: increased delivery of radioimmunoconjugate by vascular effect and its retention by increased antigen expression in colon cancer xenografts.
    Kinuya S; Yokoyama K; Hiramatsu T; Tega H; Tanaka K; Konishi S; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
    Cancer Lett; 1999 Jun; 140(1-2):209-18. PubMed ID: 10403561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacologic intervention with angiotensin II and kininase inhibitor enhanced efficacy of radioimmunotherapy in human colon cancer xenografts.
    Kinuya S; Yokoyama K; Kawashima A; Hiramatsu T; Konishi S; Shuke N; Watanabe N; Takayama T; Michigishi T; Tonami N
    J Nucl Med; 2000 Jul; 41(7):1244-9. PubMed ID: 10914917
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhenium-186-mercaptoacetyltriglycine-labeled monoclonal antibody for radioimmunotherapy: in vitro assessment, in vivo kinetics and dosimetry in tumor-bearing nude mice.
    Kinuya S; Yokoyama K; Tega H; Hiramatsu T; Konishi S; Yamamoto W; Shuke N; Aburano T; Watanabe N; Takayama T; Michigishi T; Tonami N
    Jpn J Cancer Res; 1998 Aug; 89(8):870-8. PubMed ID: 9765625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved response of colon cancer xenografts to radioimmunotherapy with pentoxifylline treatment.
    Kinuya S; Yokoyama K; Konishi S; Li XF; Watanabe N; Shuke N; Takayama T; Bunko H; Michigishi T; Tonami N
    Eur J Nucl Med; 2001 Jun; 28(6):750-5. PubMed ID: 11440036
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Benefits of combined radioimmunotherapy and anti-angiogenic therapy in a liver metastasis model of human colon cancer cells.
    Li XF; Kinuya S; Yokoyama K; Koshida K; Mori H; Shiba K; Watanabe N; Shuke N; Michigishi T; Tonami N
    Eur J Nucl Med Mol Imaging; 2002 Dec; 29(12):1669-74. PubMed ID: 12458402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intraperitoneal radioimmunotherapy in treating peritoneal carcinomatosis of colon cancer in mice compared with systemic radioimmunotherapy.
    Kinuya S; Li XF; Yokoyama K; Mori H; Shiba K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    Cancer Sci; 2003 Jul; 94(7):650-4. PubMed ID: 12841877
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy with unlabeled and 131I-labeled pan-B-cell monoclonal antibodies in nude mice bearing Raji Burkitt's lymphoma xenografts.
    Buchsbaum DJ; Wahl RL; Normolle DP; Kaminski MS
    Cancer Res; 1992 Dec; 52(23):6476-81. PubMed ID: 1423295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretargeted radioimmunotherapy of human colorectal xenografts with bispecific antibody and 131I-labeled bivalent hapten.
    Gautherot E; Rouvier E; Daniel L; Loucif E; Bouhou J; Manetti C; Martin M; Le Doussal JM; Barbet J
    J Nucl Med; 2000 Mar; 41(3):480-7. PubMed ID: 10716323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Experimental radioimmunotherapy with 186Re-MAG3-A7 anti-colorectal cancer monoclonal antibody: comparison with 131I-counterpart.
    Kinuya S; Yokoyama K; Kobayashi K; Motoishi S; Onoma K; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    Ann Nucl Med; 2001 Jun; 15(3):199-202. PubMed ID: 11545188
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
    Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
    Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fractionated radioimmunotherapy of human colon carcinoma xenografts with 131I-labeled monoclonal antibody CC49.
    Buchsbaum D; Khazaeli MB; Liu T; Bright S; Richardson K; Jones M; Meredith R
    Cancer Res; 1995 Dec; 55(23 Suppl):5881s-5887s. PubMed ID: 7493364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced efficacy of 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model.
    Kelly MP; Lee FT; Smyth FE; Brechbiel MW; Scott AM
    J Nucl Med; 2006 Apr; 47(4):716-25. PubMed ID: 16595507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimizing radioimmunotherapy by matching dose distribution with tumor structure using 3D reconstructions of serial images.
    Flynn AA; Pedley RB; Green AJ; Boxer GM; Boden R; Begent RH
    Cancer Biother Radiopharm; 2001 Oct; 16(5):391-400. PubMed ID: 11776756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dosimetric evaluation and radioimmunotherapy of anti-tumour multivalent Fab' fragments.
    Casey JL; Pedley RB; King DJ; Green AJ; Yarranton GT; Begent RH
    Br J Cancer; 1999 Nov; 81(6):972-80. PubMed ID: 10576653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts.
    Kinuya S; Kawashima A; Yokoyama K; Koshida K; Konishi S; Watanabe N; Shuke N; Bunko H; Michigishi T; Tonami N
    J Nucl Med; 2002 Aug; 43(8):1084-9. PubMed ID: 12163635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Improved radioimmunotherapeutic efficacy of an anticarcinoma monoclonal antibody (131I-CC49) when given in combination with gamma-interferon.
    Greiner JW; Ullmann CD; Nieroda C; Qi CF; Eggensperger D; Shimada S; Steinberg SM; Schlom J
    Cancer Res; 1993 Feb; 53(3):600-8. PubMed ID: 8425194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.